We have characterized the interaction between apolipoprotein E (apoE) and amyloid ␤ peptide (A␤) in the soluble fraction of the cerebral cortex of Alzheimer's disease (AD) and control subjects. Western blot analysis with specific antibodies identified in both groups a complex composed of the full-length apoE and A␤ peptides ending at residues 40 and 42. The apoE-A␤ soluble aggregate is less stable in AD brains than in controls, when treated with the anionic detergent SDS. The complex is present in significantly higher quantity in control than in AD brains, whereas in the insoluble fraction an inverse correlation has previously been reported. Moreover, in the AD subjects the A␤ bound to apoE is more sensitive to protease digestion than is the unbound A␤. Taken together, our results indicate that in normal brains apoE efficiently binds and sequesters A␤, preventing its aggregation. In AD, the impaired apoE-A␤ binding leads to the critical accumulation of A␤, facilitating plaque formation.
Apolipoprotein E (apoE) is a polymorphic plasma glycoprotein that binds cholesterol and other lipids, mediating their transport into the cell (1, 2) . In brain, apoE is expressed mainly in glial cells, and it is thought to be implicated in neuronal regeneration (3, 4) . Although the allele of apoE isoform 4 (apoE 4) is strongly associated with late-onset familial and sporadic Alzheimer's disease (AD) (5, 6) , the role of apoE in the pathogenesis of AD is still unclear. The presence of apoE in amyloid plaques (7, 8) , the positive correlation between amyloid burden and the frequency of allele 4 (9, 10), and the in vitro binding of apoE to the amyloid ␤-peptide (A␤) (11) , the major component of AD amyloid (12, 13) , strongly suggest that apoE influences the rate of cerebral amyloidogenesis. However, it is still debated whether apoE 4 promotes or inhibits the aggregation and polymerization of A␤ (14) (15) (16) .
We have previously proposed that a water-soluble form of A␤ (sA␤) is an early marker of amyloid formation because it is detectable only in brains of subjects with AD or at risk for AD, such as young individuals with Down's syndrome who still lack plaques or amyloid deposits, whereas it is undetectable in normal brain tissue (17, 18) . These findings point to a mechanism that prevents the accumulation of A␤ under normal conditions. Because of its capability to bind A␤ peptides in vitro and its involvement in AD, apoE is the best candidate to play a role in sequestering and clearing sA␤ in brain.
In this study, we investigated the interaction between apoE and A␤ in the soluble fraction of AD and control brains associated with various apoE genotypes.
MATERIALS AND METHODS
Case Selection. Cerebral cortex was obtained at autopsy from 18 patients with AD [National Institute of Neurological and Communicative Disorders and Stroke pathological criteria (19) ] and from 15 non-AD patients with other neurological (anoxic encephalopathy, telencephalic leukoencephalopathy, Huntington's disease, seizure disorder, multiple infarcts, multisystemic atrophy, Parkinson's disease) and nonneurological conditions (cardiomyopathy, liver degeneration, diabetes mellitus, bronchopneumonia, heroin intoxication, leukemia) in which the presence of amyloid deposits had been excluded by immunocytochemical analysis performed on sections obtained from the tissue sample used for the biochemical study. ApoE genotyping was carried out according to previously described methods (20) . The genotypes for AD cases were as follows: 4͞4 ϭ 3; 3͞4 ϭ 6; 3͞3 ϭ 9, and for control brains: 3͞4 ϭ 6; 3͞3 ϭ 6; 2͞3 ϭ 3.
Antibodies. Immunodetection was carried out with the monoclonal antibodies 6E10 (21) and 4G8 (21) specific for an A␤ epitope between residues 6-10 and 17-21 (Senetek, Napa, CA); the two polyclonal antibodies specific for the Ala-42 (␣A␤42) or the Val-40 (␣A␤40) residues of A␤ were purchased from Quality Controlled Biochemicals (Hopkinton, MA); the monoclonal antibody MAB1062 and the polyclonal antibody AB947 to apoE, the latter used in immunoprecipitation, were both from Chemicon. The polyclonal antibody R3660 specific for the amino-terminal region of A␤ was previously described (22) . The working dilution for all the antibodies used in detection was 1:1000. The reactivity on Western blots was visualized with the enhanced chemiluminescence system (ECL; Amersham). All the chemicals were from Sigma unless otherwise specified.
Isolation and Quantification of Soluble A␤, apoE, and apoE-A␤ Complexes. The preparation of soluble brain fractions from brain homogenates, followed by immunoprecipitation, electrophoresis, Western blotting, and densitometric quantification, was carried out as previously described (18, 22) . We used 8 l͞ml of the antibody AB947 for the immunoprecipitation of apoE after clearing the crude brain extracts from interfering immunoglobulins with a protein G͞A mixture. All the samples were analyzed at least in triplicate for quantitative purposes.
In Vitro apoE-A␤ Complex. Two different types of artificial aggregates were prepared: 600 ng of human plasma apoE (Calbiochem) was incubated at room temperature for 3 hr with 100 M A␤-(1-42) synthetic peptide (Bachem) in PBS, pH 7.4. Alternatively, 1 g of human plasma apoE (Calbiochem) was incubated for 3 days at 37°C with the A␤ peptides purified by gel filtration (see below) containing the A␤ peptides released from the apoE-A␤ complex.
Chromatography. Eight grams of gray matter as starting material from AD and non-AD subjects was processed as described before (18, 22) to obtain the soluble fraction. After immunoprecipitation of apoE and apoE-A␤ complexes with the antibody AB947 (8 l͞ml) the purified proteins were dissociated from the agarose beads with 1 M glycine at pH 2, or with 1% SDS and 10-min boiling followed by precipitation with cold acetone. The samples were then applied on a HW50F (TosoHaas, Montgomeryville, PA) column equilibrated with 0.1 M formic acid͞ammonium hydroxide, pH 7.8͞30% (vol͞ vol) acetonitrile. The column was calibrated with standard proteins and the fractions were eluted at 0.8 ml͞min, monitored by absorbance at 280 nm, and analyzed by dot-blotting using the monoclonal antibody to apoE, MAB1062, and the polyclonal antibody specific for A␤40, ␣A␤40, as detecting antibodies. Human plasma apoE (Calbiochem) and synthetic A␤-(1-40) were used as standard peptides.
Matrix-Assisted Laser Desorption Ionization Time-ofFlight (MALDI-TOF) Mass Spectrometry. After the gel filtration, the fractions corresponding to A␤ peptides released from the apoE-A␤ complex were pooled, dried under reduced pressure, and resuspended in 50 l of water. Two microliters of the resulting solution was incubated with 2 l of a freshly prepared matrix consisting of ␣-cyano-4-hydroxycinnamic acid (Aldrich) dissolved at 10 mg͞ml in 0.05 M HCl and acetonitrile͞isopropyl alcohol, 6:1.5 (vol͞vol). One microliter of the mixture was placed on the sample plate and dried at room temperature. The analysis was performed in linear positive mode on a Voyager (PerSeptive Biosystems) mass spectrometer, and 250 scans were averaged.
Protease Digestion. Brain homogenates from AD subjects with an equal protein concentration (measured with the Bradford method), were treated with proteinase K (Boehringer Mannheim) at 37°C for 1 hr. The digestion was terminated by adding phenylmethylsulfonyl fluoride at 3 mM final concentration. The homogenates were then ultracentrifuged at 100,000 ϫ g for 1 hr, and the resulting supernatants were immunoprecipitated by using the antibodies AB947 to apoE and R3660 specific for A␤ peptides. The latter does not recognize the apoE-A␤ complex when used in immunoprecipitation. Immunoblotting with 6E10 (specific for residues 6-10 of A␤) as detecting antibody was then carried out. Homogenates from the same subjects without protease digestion were processed in parallel.
RESULTS
Immunoprecipitation of A␤ peptides from soluble brain fractions with the polyclonal antibody R3660 to A␤, followed by immunoblotting and detection with the monoclonal antibody 6E10 (21) (specific for an epitope between residues 6 and 10 in the A␤ sequence), demonstrated two bands of 4.5 kDa and 4.2 kDa in all AD subjects, but not in controls (Fig. 1 ). These two bands have recently been shown to contain predominantly A␤-(1-40͞42) and pyroglutamate-modified (p) A␤-(p3-42) (22, 23) . A third A␤ band, detected with the monoclonal antibody 4G8 (21) (specific for residues 17-21 of A␤), contains mostly A␤-(11-40͞42) and pyroglutamate-modified A␤-(p11-40͞42) (22) .
The same 4.5-and 4.2-kDa A␤ bands were observed only in AD preparations, and not in control subjects, when the immunoprecipitation was carried out with AB947, the antiserum specific for human apoE, and again the monoclonal antibody 6E10 was used for immunoblot detection (Fig. 1) . Moreover, samples that had been cleared of unbound soluble A␤ by immunoprecipitation with the antibody R3660 still revealed the presence of A␤ bands in all the AD subjects in the second immunoprecipitation with the antibody AB947, which is specific for the apoE molecule. Combined, these findings suggest that in AD brains a portion of the water-soluble A␤ is bound to apoE and released after treatment with SDS prior to PAGE.
Immunoprecipitation of brain proteins with the apoE antiserum AB947, followed by immunoblotting with the monoclonal antibody MAB1062 to human apoE, demonstrated a broad band in all cases, which is significantly reduced in the AD samples, and whose lower portion comigrated with human apoE (Fig. 2a) . Immunodetection with different antibodies specific for various A␤ regions: the monoclonal antibodies 6E10 (Fig. 2b) and 4G8 (not shown), and the polyclonal antibody ␣A␤42 (specific for the carboxyl-terminal Ala in the A␤ sequence, Fig. 3a ) revealed a Ϸ40-kDa band, present in both AD and control preparations, which corresponds to the upper part of the band detected also with the MAB1062 antibody to apoE (Figs. 2a and 3b ). This band comigrated with a complex obtained in vitro by incubating human apoE and the A␤ peptides released from apoE after immunoprecipitation and gel filtration (Fig. 2b, XX) , as well as with another in vitro complex formed by human apoE and synthetic A␤-(1-42) (not shown). The same MAB1062-reacting complex was also obtained by immunoprecipitating the soluble fraction with the monoclonal antibody 4G8, specific for an epitope between residues 17 and 21 in the A␤ sequence (Fig. 3b) . The gel mobility, the reactivity with various antibodies specific for both proteins, and the comigration with aggregates formed in vitro indicate that the Ϸ40-kDa band corresponds to a complex formed by the full-length apoE and the water-soluble A␤x-42. Moreover, the aggregate isolated from control cases is completely SDS resistant (Fig. 4a) , whereas in the AD brain extracts the A␤ peptides are easily released from the complex (Figs. 1 and 4a ). The reactivity of the aggregate with the anti-apoE antibody MAB1062 was 40% lower in soluble preparations from AD brains than in control cases (P Ͻ 0.005) (Fig. 4b) . No significant differences among apoE genotypes were found, except for a lower reactivity in AD subjects homozygous 4 (Figs. 2 and 4a) . Immunoprecipitation of soluble brain fractions with the apoE antibody AB947, followed by gel filtration, led to the separation of an high molecular mass protein fraction that immunoreacted in dot-blot analysis with the anti-apoE antibody MAB1062, and with the antibody ␣A␤40, which is specific for the carboxyl-terminal Val-40 of A␤, in both AD and control tissues (Fig. 5a ). This finding is consistent with the presence of high molecular mass aggregates (24, 25) in addition to the monomeric aggregate present in the Ϸ40-kDa region (Fig. 5 , fractions 6 and 7) equally immunoreactive with both antibodies. Moreover, the reactivity with the antibodies ␣A␤40 and ␣A␤42 (Fig. 3a) indicates that both A␤40 and A␤42 aggregate with apoE. In contrast, the fractions below a molecular mass of 8 kDa (Fig. 5, fractions 10-12 ) react with the antibody ␣A␤40 in AD cases only. To verify whether the instability of the complex in AD brains was reversible in vitro and whether, in our conditions, the instability was because of an impaired binding capacity of apoE, these fractions were incubated with human plasma apoE to produce an in vitro aggregate that would mimic the complex purified from the brain. In SDS͞PAGE this in vitro complex was resistant to the detergent treatment and comigrated at Ϸ40 kDa with the apoE-A␤ aggregates extracted from both AD and control brains (Fig. 2b, XX) . To further investigate the composition of the pool of A␤ bound to apoE, the same fractions purified in gel filtration were analyzed by MALDI-TOF mass spectrometry. This analysis demonstrated a substantial amino-and carboxyl-terminal heterogeneity of A␤ peptides (Fig. 5b) , with a similar pattern for the apoE 3 and 4 homozygous AD subjects. No A␤ peptides were detected in the brain extracts purified from non-AD subjects. To clarify whether the A␤ bound to apoE and the unbound pool of water-soluble A␤ could be characterized and differentiated also on the basis of their resistance to proteases, we treated the AD brain homogenates with proteinase K. The A␤ peptides present in the complex with apoE (Fig. 6 , white bars) were completely digested when treated with proteinase K at 50 g͞ml, whereas the unbound, soluble A␤ (Fig. 6 , gray bars) was resistant to proteinase K at 300 g͞ml.
DISCUSSION
This study demonstrates that A␤ is bound to apoE, with which it forms a soluble complex of approximately 40 kDa present in both AD and control brains. The A␤ present in plaque-free control brains was found to be entirely bound to apoE in soluble complexes that are resistant to dissociation when treated with SDS. Therefore, it is likely that the undetectability of water-soluble A␤ peptides in normal brains originally reported by us (17) is due to their binding and sequestration by apoE. The higher sensitivity to proteinase K of the A␤ pool Fig. 2a . This band is underrepresented in AD subjects and in the subject homozygous 4 is visible only after a longer exposure. The polyclonal antibody AB947 alone (B) does not detect any band in the region of the apoE-A␤ complex. The lower portion of the gel, immunostained with the monoclonal anti-A␤ antibody 6E10, reveals the typical A␤ pattern for the AD cases, indicating that a portion of A␤ peptides is released from the complex with apoE after SDS͞PAGE, only in AD samples. (b) Quantification of the 34-to 40-kDa band detected in immunoblotting after immunoprecipitation with the antibody to apoE AB947 demonstrates a 40% lower reactivity in AD than in control (CO) subjects. ‫,ء‬ P Ͻ 0.005. complexed with apoE suggests that apoE maintains the A␤ peptides in a soluble aggregate that is sensitive to proteases (26) or might be removed by cell receptors as previously suggested (27) . Surprisingly, when A␤ peptides are not bound to apoE, they are more resistant to the proteolytic activity. This finding implies that apoE facilitates the degradation of A␤ peptides and that the unbound A␤, although soluble, is in an aggregated state. Nevertheless, we cannot rule out the possibility that another molecule(s) protects the soluble A␤ from the protease action when it is not bound to the apoE.
In contrast, in AD brains most of the A␤ peptides that are bound to apoE are released by SDS treatment (Figs. 1 and 4a) . Consistent with this finding, the apoE-A␤ stable complexes are present in significantly lesser amount in soluble extracts of AD brains than in controls. This result is in agreement with a previous study (24) , which has demonstrated a reversed equilibrium between soluble and insoluble A␤-apoE complexes in AD brain. The unstable binding between the two molecules might increase the A␤ concentration and trigger the accumulation of A␤ up to the critical point of nucleation (28) and subsequent polymerization. Polymerized A␤ would also interact with and incorporate the apoE-A␤ complex. At this stage, most of the apoE-A␤ aggregate would shift to the insoluble fraction and participate in the formation of amyloid fibers (7, 8, 24) . The above-mentioned high levels of insoluble apoE-A␤ complexes in AD (24) , their low level in control subjects, and the direct identification of apoE in amyloid fibers (6, 24) argue in favor of this hypothesis. An opposite role of apoE in normal and pathological conditions is consistent with the apparently discordant data obtained from experiments in vitro in which apoE was shown to inhibit A␤ aggregation at nanomolar (physiological) concentrations of A␤ (16) , whereas a reverse effect was observed with micromolar A␤ doses (14) . Moreover, the presence of apoE in diffuse plaques in young subjects with Down's syndrome (29, 30) is consistent with the role of the apoE-A␤ complex in promoting plaque formation. An unbalanced equilibrium between soluble and insoluble complex may have further consequences for neurodegeneration. The engagement of apoE in the formation of amyloid fibrils is likely to affect its overall normal function. A decreased level of soluble apoE has been reported in the frontal cortex of AD subjects (31) , and the absence of functional apoE in apoEknockout mice results in synaptic and dendritic abnormalities (32) , learning deficits (33, 34) and decreased levels of choline acetyltransferase (34) . These changes can be reverted with the introduction of recombinant apoE (35) , which suggests that apoE plays a critical role in the stability of the neural network and processes of memory.
Our hypothesis would also explain the recent finding of the lack of plaque formation in an apoE-knockout transgenic mouse that over-expresses mutant amyloid precursor protein (36) . In this model, the lack of apoE would block the formation of the apoE-A␤ complex hindering amyloid deposition.
The stability of the aggregate formed by apoE and A␤ can be reduced by changes in either A␤ or apoE molecules (37) (38) (39) . The latter possibility is supported by the finding that the A␤ released from the complex with apoE forms an SDS-stable aggregate in vitro with human plasma apoE (Fig. 2b, XX) . The aim of our experiment was to verify if the instability of the complex in AD brains was because of a defective apoE and if the process was reversible (at least in vitro). The apoE used in our experiments is a mixture of the three major human isoforms, and the contribution of each subtype to the reaggre- FIG. 5 . Gel filtration and mass spectrometric analysis of A␤ peptides released from the apoE-A␤ complex. (a) Dot-blot analysis of the fractions collected after gel filtration of brain soluble preparation immunoprecipitated with the AB947 antibody to apoE from AD and control (CO) subjects. The immunodetection was carried out with the antibodies MAB1062 (to apoE) and ␣A␤40 (to A␤40). Both antibodies detected reactive proteins in the high molecular mass region (fractions 1 and 2) as well as in the 30-to 40-kDa region (fractions 6 and 7), the latter co-eluting with human plasma apoE. The antibody ␣A␤40 detects positive fractions also in the low molecular mass region (fractions 10-12) only in AD preparations; these fractions correspond to the A␤ peptides released from the complex with apoE. (b) After immunoprecipitation with AB947 (to apoE) and gel filtration on a HW50 column the fractions 10-12 from AD and control subjects were analyzed by MALDI-TOF mass spectrometry. The AD samples reveal various carboxyl-and amino-terminally truncated A␤ peptides, whereas in control brains no A␤ peptides are detectable (data not shown). The A␤ peaks are identified by their size in Da, while ''m'' identifies nonspecific signals due to the matrix.
FIG. 6. Proteinase K treatment of free and apoE-bound soluble A␤ in AD subjects. The total brain homogenate from AD subjects was treated with increasing concentrations of proteinase K (PK) for 1 hr at 37°C. The soluble fraction was then analyzed in SDS͞PAGE. The unbound pool of A␤ (gray bars) and the apoE-bound A␤ (white bars), detected and quantified with the monoclonal antibody 6E10, show different sensitivities to proteinase K. The A␤ present in the complex with apoE is completely digested after treatment with proteinase K at 50 g͞ml, whereas the unbound soluble A␤ is resistant to proteinase K at concentrations up to 300 g͞ml. gation process is unknown. With reference to previous published work (40) the contribution of the apoE 3 should be more significant. On the other hand, if an impaired binding is the critical step in the failure of apoE in sequestering and clearing A␤ peptides, the genetic predisposition related to the 4 allele might be easily explained by a constitutively weaker affinity of apoE 4 for A␤. An isoform-specific binding has been described in vitro (11, 27, 40) , and a decreased amount of apoE 4 was detected in the plasma and in the cerebrospinal fluid of 4 homozygous subjects (41) (42) (43) , suggesting that the total apoE 4 content might be insufficient to clear and sequester an increased amount of soluble A␤. In fact, in our analysis the presence of the complex in the AD 4 homozygous subjects is decreased, although not significantly. However, we did not find any statistically significant variation in the presence, type, and amount of the SDS-stable apoE-A␤ complex in relation to the apoE genotype in control subjects, although control subjects homozygous for the 4 allele were not available for this study. We can only hypothesize that a more relevant effect of the genotype could be present in the early stage of the disease; since our analysis on AD subjects describes the end stage of the pathological process and in the non-AD subjects the pathology never started. Moreover, the mass spectrometric study in the AD subjects indicates that the apoE-A␤ complexes are composed of the entire apoE molecule and different A␤ peptides with both Val-40 and Ala-42 carboxyl termini and that the forms of A␤ peptides released from the complex were identical in AD subjects apoE 3 and 4 homozygous. Taken together, our results indicate that in pathological conditions the apoE-A␤ complex became unstable and insoluble, whereas in normal brains apoE binds and sequesters A␤, preventing its aggregation.
